ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Dr Mariana Chavez MacGregor reports on advances from ASCO 2025, emphasizing treatment de-escalation and emerging tools like ctDNA for personalized care.

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed ...

An analysis of oral presenters at ASCO Annual Meeting revealed considerable disparities based on career stage, gender, subspecialty and geographic region.Mid- to late-career medical oncologists from ...

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.